Wet Age Related Macular Degeneration (AMD) Market Research report By Drug Type (Anti-VEGF Drugs, Photodynamic Therapy, Others), Route of Administration (Intravitreal, Intravenous, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), End-User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Others), and by Region- Global Forecast to 2034
June-2025 Formats | PDF | Category: Healthcare | Delivery: 24 to 72 Hours
“The Wet Age Related Macular Degeneration (AMD) Market industry is expected to expand from 11.6 Billion in 2025 to $ 17.8 Billion in 2034, with a compound annual growth rate of 5.8% “
Wet Age Related Macular Degeneration (AMD) Market: Overview and Growth in the Upcoming Year
As the world’s population ages, age-related macular degeneration (AMD) is becoming more common. Wet Age Related Macular Degeneration (AMD), also known as neovascular AMD, is a severe and advanced form of AMD that can result in blindness if treatment is not received. This study will look at current market trends and growth projections for the Wet AMD market over the next 12 months.
Wet Age Related Macular Degeneration (AMD) is characterised by the formation of abnormal blood vessels beneath the retina, which allow blood and fluid to seep into the macula. In order to prevent irreversible damage, which leads to rapid and severe vision loss, patients must seek therapy as soon as possible.
Leading pharmaceutical companies, such as Novartis, Roche, and Regeneron Pharmaceuticals, are presently developing innovative treatments for wet AMD. These companies are focusing on the research and development of new drugs and biologics that target the pathophysiology of the disease and give patients improved safety and efficacy profiles.
Recent advancements in ophthalmology have led to the introduction of novel therapeutic approaches for Wet Age Related Macular Degeneration (AMD), including gene therapy, photodynamic therapy, and intravitreal injections. These treatments aim to enhance patients’ visual outcomes by halting the growth of abnormal blood vessels, reducing inflammation, and preserving retinal function.
For Insights Consultancy’s latest market intelligence study, “Global Wet Age Related Macular Degeneration (AMD) Market 2025, Growth Opportunities, and Forecast,” provides a comprehensive analysis of the Food industry. The report includes demand analysis, industry insights, competition intelligence, and a customer database. It also offers strategic insights into future trends, growth determinants, supplier landscape, demand landscape, CAGR, and pricing analysis. The study also includes Porter’s Five Forces Analysis, PESTLE Analysis, Value Chain Analysis, 4 Ps’ Analysis, Market Attractiveness Analysis, BPS Analysis, and Ecosystem Analysis.
*Note: Sample of the report provides details on the scope and coverage, table of contents, research methodology, and Sample Framework of the report. Actual report of 110+ is available for purchase to all the interested stakeholders.
Wet Age Related Macular Degeneration (AMD) Market Key Takeaways
Regional Contribution to Market in 2024:
When looking at the regional contributions to the Wet Age Related Macular Degeneration market in 2024, Asia Pacific is undoubtedly positioned to grow at the fastest rate. Due to the rapidly ageing population and increasing prevalence of AMD in countries like China and Japan, the Asia Pacific region is expected to drive the market’s significant growth.
Fastest Growing Region and Leading Region:
Asia Pacific is growing at the fastest rate. However, due to its advanced healthcare system, extensive awareness of AMD, and the presence of significant industry players, North America still commands the largest market share. However, the growth rates in North America are more stable than the dynamic increase seen in Asia Pacific.
Market Breakdown by Type:
The market segmentation by type reveals that one of the main factors propelling the growth of the wet AMD market is the increasing prevalence of neovascular (wet) AMD, which accounts for the majority of cases. This kind of AMD is characterised by the aberrant growth of blood vessels beneath the retina, which can lead to vision loss and other issues if left untreated.
On the other hand, non-neovascular (dry) AMD also makes up a sizable share of the market, particularly in places with an ageing population. To properly treat and manage patients, healthcare providers need to be able to differentiate between the two types of AMD.
Fastest Growing Sub-Segment:
Out of all the market breakdowns by kind, the intravitreal injections subsegment is expanding at the fastest rate. By injecting anti-VEGF medications directly into the eye, these injections target the abnormal blood vessel growth associated with neovascular AMD. As more patients opt for this minimally invasive treatment option, it is expected that demand for intravitreal injections will rise in the coming years.
Key Applications (2024 Market Share):
Wet age-related macular degeneration is primarily used in the market for surgical procedures, drugs, and diagnostic tools. While fundus photography and optical coherence tomography (OCT) are crucial for early detection and tracking the progression of AMD, therapeutics such as anti-VEGF medications are the cornerstone of treatment for neovascular AMD.
Fastest Growing Application (Forecast Period 2025 to2034)
Going forward, gene therapy is anticipated to be the application in the Wet Age Related Macular Degeneration market with the fastest rate of growth. Gene therapy may eventually result in long-term management strategies or cures for AMD with further genetic engineering research and development.
As advances in technology and personalised medicine continue to drive innovation in the healthcare industry, gene therapy offers a novel approach to treating AMD at the molecular level. Between 2025 and 2034, gene therapy applications for Wet AMD are expected to grow rapidly, drastically altering the range of treatment options available to patients.
Report Attributes
Metric | Details |
Market Size in 2025 | USD 11.6 Billion |
Projected Market Size in 2034 | USD $ 17.8 Billion |
CAGR (2025 – 2034) | 5.8% |
Market Segmentation | By Drug Type, by Distribution Channel, and By Region |
Top Key Players | Novartis AG, Bayer AG, Roche Holding AG, Pfizer Inc., Allergan plc, Alcon Inc., Santen Pharmaceutical Co., Ltd., Kanghong Pharmaceutical Group Co., Ltd., Ophthotech Corporation, Adverum Biotechnologies, Inc., Graybug Vision, Inc., Kodiak Sciences Inc., Opthea Limited, Biogen Inc., Genentech, Inc., Samsung Bioepis Co., Ltd., PanOptica, Inc., Iconic Therapeutics, Inc., Hemera Biosciences, Inc. |
Customization Scope | Report customization (equivalent to up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Top Companies Covered In This Report:
The Wet Age Related Macular Degeneration (AMD) Market’s competitive environment provides a thorough examination of the major participants. Company summaries, financial results, revenue generation, market potential, R&D expenditures, new market strategies, regional presence, strengths and weaknesses, product launches, product range, and application leadership are some of the data it contains. These statistics particularly relate to the businesses’ operations and areas of concentration in the Wet Age Related Macular Degeneration (AMD) market.
- Novartis AG
- Bayer AG
- Roche Holding AG
- Pfizer Inc.
- Allergan plc
- Alcon Inc.
- Santen Pharmaceutical Co., Ltd.
- Kanghong Pharmaceutical Group Co., Ltd.
- Ophthotech Corporation
- Adverum Biotechnologies, Inc.
- Graybug Vision, Inc.
- Kodiak Sciences Inc.
- Opthea Limited
- Biogen Inc.
- Genentech, Inc.
- Samsung Bioepis Co., Ltd.
- PanOptica, Inc.
- Iconic Therapeutics, Inc.
- Hemera Biosciences, Inc.
Industry News
February 04, 2025 FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Basel, 04 February 2025 – Roche announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide. Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina specialists and their patients with DME.
May 22, 2025 FDA approves Roche’s Susvimo for diabetic retinopathy
Basel, 22 May 2025 – Roche announced that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a potentially blinding condition that affects almost 10 million people in the US and more than 100 million people globally. It is the first and only FDA-approved continuous delivery treatment shown to maintain vision in people with DR with just one refill every nine months. Susvimo is now available to US retina specialists and their patients with DR who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2034, Y-o-Y growth rate, and CAGR):
Segment ByRoute of Administration
- Intravitreal
- Intravenous
- Others
Segment by Drug Type
- Anti-VEGF Drugs
- Photodynamic Therapy
- Others
Segment by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Regional Deep-dive Analysis:
The report provides in-depth qualitative and quantitative data on the Wet Age Related Macular Degeneration (AMD) Market for all of the regions and countries listed below:
North America
United State
The United States accounts for a significant share of the wet AMD market in North America. Age-related eye issues are widespread, and the country’s healthcare system is well-established. Due to continued R&D efforts and the existence of significant industry competitors, the US market is growing.
Canada
Canada also holds a significant market share in the wet AMD market. As the country’s population ages, wet AMD and other age-related eye conditions are more likely to develop. Because of the government’s efforts to increase awareness about eye health and the availability of innovative treatment alternatives, the Canadian market is expanding.
Asia-Pacific
China
The wet AMD industry is significantly impacted by China, one of the largest countries in the Asia-Pacific region. China’s ageing population and growing awareness of eye health are driving up demand for innovative AMD treatments. The government’s efforts to improve healthcare facilities and increase access to innovative treatments are also driving industry growth. Leading pharmaceutical companies are spending money on research and development to give Wet AMD patients in China access to cutting-edge treatment options.
Japan
Japan is well known for its advanced healthcare system and cutting-edge medical technology. Because AMD is so common in the country, the market for wet AMD treatments is growing. Because of its proactive dedication to early diagnosis and treatment, Japan is setting the standard in this field of research. Japanese pharmaceutical companies are collaborating with foreign partners to develop novel treatments for wet AMD in an attempt to improve patient outcomes and quality of life.
India
India’s sizable population and growing healthcare expenses make it a promising market for wet AMD. The country’s strong research capabilities and highly skilled healthcare workforce are driving innovation in the field of ophthalmology.
Europe
Germany
In Germany, AMD is fairly prevalent, particularly in older people. The German healthcare system ensures that patients have access to the most up-to-date treatments by providing full coverage for wet AMD treatments. Cost-effectiveness and innovation are given top priority in Germany’s competitive wet AMD therapy market.
France
In France, AMD is on the rise due to the country’s ageing population. The French healthcare system reimburses patients for wet AMD treatments. The French market for wet AMD treatments is a mix of domestic and foreign pharmaceutical companies.
United Kingdom
The prevalence of AMD is steadily rising in the UK due to an ageing population. The National Health Service (NHS) offers a range of treatment options for patients with wet AMD, including anti-VEGF injections and photodynamic therapy. In the UK’s well-established wet AMD treatment market, several pharmaceutical companies are fighting for market supremacy.
Italy
The growing number of senior citizens in Italy is contributing to an increase in the prevalence of AMD. The Italian healthcare system provides coverage for wet AMD treatments, ensuring that patients receive care on schedule. The wet AMD treatment industry is flourishing in Italy thanks to a focus on patient outcomes and customised medication.
Middle East and Africa
Saudi Arabia
Wet AMD is becoming more common in Saudi Arabia due to the same causes as in the United Arab Emirates. Addressing the issues raised by Wet AMD has been made possible in large part by government programmes to improve healthcare infrastructure and encourage early identification and treatment of eye illnesses.
UAE
Similar to the UAE, Saudi Arabia is seeing an increase in the prevalence of wet AMD. Addressing the issues raised by Wet AMD has been made possible in large part by government programmes to improve healthcare infrastructure and encourage early identification and treatment of eye illnesses. With new treatment options and an increasing emphasis on preventive care, the market for wet AMD therapies in Saudi Arabia is expected to increase significantly.
South Africa
The elderly are particularly vulnerable to Wet AMD, which accounts for a significant portion of cases in South Africa. The lack of access to specialised eye care services in rural areas hinders the timely detection and treatment of wet AMD. The government and non-profit organisations’ efforts to increase healthcare services and awareness about eye health are expected to boost the Wet AMD market in South Africa.
Nigeria
Nigeria is seeing a steady increase in the prevalence of wet AMD, and people are realising the importance of maintaining good eye health. Effective treatment of Wet AMD cases is still hampered by inadequate infrastructure and resources for eye care services.
The research provides answers to the following key questions:
- What is the expected growth rate of the Wet Age Related Macular Degeneration (AMD) Market from 2025-2034?
- What are the key driving forces shaping the market during the forecast period?
- Who are the major market vendors and what winning strategies have helped them occupy a strong foothold in the Wet Age Related Macular Degeneration (AMD) Market?
- What are the prominent market trends influencing the market’s development?
Key insights provided by the report that could help you take critical strategic decisions?
- Regional reports analyse product/service consumption and market factors in each region.
- Reports highlight possibilities and dangers for suppliers in the Wet Age Related Macular Degeneration (AMD) Market business globally.
- The report identifies regions and sectors with the highest growth potential.
- It provides a competitive market ranking of major companies, as well as information on new product launches, partnerships, business expansions, and acquisitions.
- The report includes a comprehensive corporate profile with company overviews, insights, product benchmarks, and SWOT analysis for key market participants.
Customization: We can provide following things
1) On request more company profiles (competitors)
2) Data about particular country or region
3) We will incorporate the same with no additional cost (Post conducting feasibility).
Any Requirement Contact us: https://www.forinsightsconsultancy.com/contact-us/
Table of Contents
For TOC Contact us: https://www.forinsightsconsultancy.com/contact-us/
